The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Biocon Ltd. is seeking regulatory approval to launch generic versions of weight-loss drugs Ozempic and Wegovy in Canada, following patent expiration next year.

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...